Market Overview

Wedbush Upgrades Illumina To Outperform, Shares Rise

Related ILMN
8 Biggest Price Target Changes For Friday
Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial
Leading Biotech Stocks Among This Top Sector's Biggest Bets (Investor's Business Daily)

Analysts at Wedbush upgraded Illumina (NASDAQ: ILMN) from Neutral to Outperform.

The price target for Illumina has been raised from $165.00 to $200.00.

Illumina shares have jumped 117.07% over the past 52 weeks, while the S&P 500 index has gained 19.93% in the same period.

Illumina shares gained 2.93% to $175.48 at 10:50 a.m. ET.

Latest Ratings for ILMN

Jul 2018Morgan StanleyMaintainsUnderweightUnderweight
Jul 2018Cowen & Co.MaintainsOutperformOutperform
Jun 2018CitigroupMaintainsBuyBuy

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: WedbushUpgrades Analyst Ratings


Related Articles (ILMN)

View Comments and Join the Discussion!